-
公开(公告)号：US20130164379A1
公开(公告)日：2013-06-27
申请号：US13668075
申请日：2012-11-02
申请人： Andrei L. Gartel , Ming Wang
发明人： Andrei L. Gartel , Ming Wang
CPC分类号： A61K31/69 , A61K9/1075 , A61K38/04 , A61K38/12 , A61K45/06 , A61K2300/00
摘要： Nanoparticle micelle coated compositions and methods for treating a subject having a solid tumor are disclosed. The compositions comprise thiostrepton and a micelle-forming lipid wherein the thiostrepton is encapsulated inside a nanoparticle comprising the micelle-forming lipid. Pharmaceutical compositions comprising a thiostrepton-micelle composition are also disclosed.
摘要翻译： 公开了纳米颗粒胶束涂层组合物和用于治疗具有实体瘤的受试者的方法。 所述组合物包含硫代三环素和形成胶束的脂质，其中硫代三环糊精包封在包含胶束形成脂质的纳米颗粒内。 还公开了包含硫链突起 - 胶束组合物的药物组合物。
-
2.发明申请IDENTIFICATION AND USE OF AGENTS THAT MODULATE ONCOGENIC TRANSCRIPTION AGENT ACTIVITY 失效鉴定和使用调节基因转录代谢活性的试剂公开(公告)号：US20080152618A1
公开(公告)日：2008-06-26
申请号：US11865410
申请日：2007-10-01
IPC分类号： A61K38/19 , C12Q1/02 , A61K38/16 , A61P35/00 , A61K31/4353
CPC分类号： A61K31/4353 , C12Q1/6897 , G01N33/68 , G01N2333/4703 , G01N2500/10
摘要： Embodiments of the invention provides, among other things, methods for identifying agents that inhibit oncogenic transcription factors, induce apoptosis, inhibit the growth of transformed cells and cancer cells, and potentiate the effects of other agents that induce apoptosis and that inhibit the growth of transformed cells and cancer cells. Embodiments of the invention further provide compositions useful for the same comprising an agent the inhibits one or more oncogenic transcription factors and an agent that induces apoptosis, particular compositions wherein the apoptotic effect of the combination is greater than either agent by itself. Embodiments of the invention further provide for the use of such agents and compositions to treat cancer. In illustrative embodiments the agents that inhibit transcription factor activity are thiazole antibiotics, such as Siomycin and thiostrepton, and the apoptosis inducing agent is a member of the TNF ligand superfamily, such as TNF-alpha. In illustrative embodiments the cancers are those in which both the FoxM1 and the NF-kB oncogenic pathways are activated.
摘要翻译： 本发明的实施方案尤其提供用于鉴定抑制致癌转录因子，诱导凋亡，抑制转化细胞和癌细胞生长的试剂的方法，以及增强诱导细胞凋亡和抑制转化的细胞生长的其它试剂的作用 细胞和癌细胞。 本发明的实施方案还提供了可用于其的组合物，其包含抑制一种或多种致癌转录因子的试剂和诱导凋亡的试剂，其中组合的凋亡作用本身大于任一试剂的特定组合物。 本发明的实施方案还提供了这些药剂和组合物用于治疗癌症的用途。 在说明性实施方案中，抑制转录因子活性的试剂是噻唑类抗生素，如西莫霉素和硫链丝氨酸，凋亡诱导剂是TNF配体超家族成员，如TNF-α。 在说明性实施方案中，癌症是FoxM1和NF-kB致癌途径都被激活的癌症。
-
3.发明授权Identification and use of agents that modulate oncogenic transcription agent activity 失效识别和使用调节致癌转录因子活性的试剂公开(公告)号：US08029980B2
公开(公告)日：2011-10-04
申请号：US11865410
申请日：2007-10-01
CPC分类号： A61K31/4353 , C12Q1/6897 , G01N33/68 , G01N2333/4703 , G01N2500/10
摘要： Embodiments of the invention provides, among other things, methods for identifying agents that inhibit oncogenic transcription factors, induce apoptosis, inhibit the growth of transformed cells and cancer cells, and potentiate the effects of other agents that induce apoptosis and that inhibit the growth of transformed cells and cancer cells. Embodiments of the invention further provide compositions useful for the same comprising an agent the inhibits one or more oncogenic transcription factors and an agent that induces apoptosis, particular compositions wherein the apoptotic effect of the combination is greater than either agent by itself. Embodiments of the invention further provide for the use of such agents and compositions to treat cancer. In illustrative embodiments the agents that inhibit transcription factor activity are thiazole antibiotics, such as Siomycin and thiostrepton, and the apoptosis inducing agent is a member of the TNF ligand superfamily, such as TNF-alpha. In illustrative embodiments the cancers are those in which both the FoxM1 and the NF-kB oncogenic pathways are activated.
摘要翻译： 本发明的实施方案尤其提供用于鉴定抑制致癌转录因子，诱导凋亡，抑制转化细胞和癌细胞生长的试剂的方法，以及增强诱导细胞凋亡和抑制转化的细胞生长的其它试剂的作用 细胞和癌细胞。 本发明的实施方案还提供了可用于其的组合物，其包含抑制一种或多种致癌转录因子的试剂和诱导凋亡的试剂，其中组合的凋亡作用本身大于任一试剂的特定组合物。 本发明的实施方案还提供了这些药剂和组合物用于治疗癌症的用途。 在说明性实施方案中，抑制转录因子活性的试剂是噻唑类抗生素，如西莫霉素和硫链丝氨酸，凋亡诱导剂是TNF配体超家族成员，如TNF-α。 在说明性实施方案中，癌症是FoxM1和NF-kB致癌途径都被激活的癌症。
-
-
搜索结果
3 条记录 (耗时 0.011 秒)
